Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

PaperCitations, authors & open-access status

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 279 citations, 2020 year and hybrid oa status.

279
Citations
2020
Year
hybrid
OA Status

Related on ScholarIQ

Myung‐Ju Ahn
Author
Frances A. Shepherd
Author
Hiroaki Akamatsu
Author
Yi‐Long Wu
Author
Annals of Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
470M+ articles · free account